PR Newswire·Oct 20, 2026, 4:17 PM ET

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics disclosed on June 30, 2026, that the FDA issued a second Complete Response Letter regarding its resubmitted application for oxylanthanum carbonate.
The FDA cited the same third-party manufacturing deficiencies in the second letter that were identified in a previous letter issued in June 2025.
The FDA has not yet inspected the third-party manufacturing facility as part of its review of the resubmitted application.
Unicycive stated that the second letter did not raise concerns regarding the treatment's clinical efficacy or safety data.
Following the disclosure, Unicycive stock fell $3.01 per share, or 39.1%, to close at $4.69 on June 30, 2026.
Fletcher Moore Law PLLC is inviting Unicycive shareholders to contact them at fletcher@fmoorelaw.com to potentially seek monetary damages, corporate governance reforms, reimbursement, or incentive awards on a contingency fee basis.